Press "Enter" to skip to content

Gilead Sciences Inc  Shares Crashes

Gilead Sciences Inc. shares slipped 0.12% to $67.93 Wednesday. This proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.12% to 4,374.30 and the Dow Jones Industrial Average DJIA rising 0.13% to 34,933.23.

Gilead Sciences Inc. closed $11.01 below its 52-week high ($78.94), which the company reached on July 20th. The stock underperformed when compared to some of its competitors Wednesday, as Johnson & Johnson JNJ rose 0.68% to $170.42, Merck & Co. Inc. MRK rose 0.01% to $77.62, and AbbVie Inc. ABBV rose 0.64% to $117.36.

Gilead Sciences Inc trading volume (5.9 M) remained 722,062 below its 50-day average volume of 6.6 M.This was the stock’s third consecutive day of losses. Gilead Sciences Inc full-year Zacks Consensus Estimates are calling for earnings of $7.07 per share and revenue of $24.74 billion. These results would represent year-over-year changes of -0.28% and +0.22%, respectively.The Zacks Rank system ranges from #1 to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. GILD is currently sporting a Zacks Rank of #4.

In terms of valuation, GILD is currently trading at a Forward P/E ratio of 9.6. This valuation marks a discount compared to its industry’s average Forward P/E of 23.23.Investors should also note that GILD has a PEG ratio of 0.63 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock’s expected earnings growth rate. The Medical – Biomedical and Genetics were holding an average PEG ratio of 1.39 at yesterday’s closing price.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *